Mecasermin rinfabate is a Recombinant Protein owned by Insmed, and is involved in 5 clinical trials, of which 2 were completed, 2 are ongoing, and 1 is planned.
Mecasermin supplies recombinant-DNA-origin IGF-1, which binds to the Type I IGF-1 receptor and and human insulin-like growth factor-binding protein-3 (rhIGFBP-3)0. This receptor exerts intra-cellular signaling activity in a number of processes involved in statural growth, including mitogenesis in multiple tissue types, chondrocyte growth and division along cartilage growth plates, and increases in organ growth.
The revenue for Mecasermin rinfabate is expected to reach a total of $1.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Mecasermin rinfabate NPV Report.
Mecasermin rinfabate Overview
Mecasermin rinfabate (Iplex) is a recombinant human biologic protein complex of insulin-like growth factor-1 (IGF-1). It is formulated as injectable solution for subcutaneous route of administration. It is indicated in the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD).
Mecasermin rinfabate (Iplex) is under development for treatment of chronic respiratory morbidity (CRM) including bronchopulmonary dysplasia (BPD), retinopathy of prematurity and severe intraventricular hemorrhage. It was also under development for the treatment of burns, myotonic dystrophy, Rabson–Mendenhall syndrome, Leprechaunism, laron syndrome, type A and type B extreme insulin resistance syndrome.
Takeda Pharmaceutical Overview
Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China and India, Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY3,569,006 million for the fiscal year ended March 2022 (FY2022), an increase of 11.6% over FY2021. In FY2022, the company’s operating margin was 12.5%, compared to an operating margin of 18.8% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 11.8% in FY2021. The company reported revenues of JPY1,002,307 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.
Quick View – Mecasermin rinfabate
|Highest Development Stage|